


FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.026000.2</b>		APPLICATION NO. <b>09/852,400</b>	
APPLICANT <b>WILLIAM L. TREPICCHIO ET AL.</b>				FILING DATE <b>May 9, 2001</b>		GROUP <b>1634</b>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
PN    ↓		GenBank database accession no. U09770 "Human cysteine-rich heart protein (hCRHP) mRNA, complete cds."					
		GenBank database accession no. U58630 "Human cysteine-rich intestinal protein (CRIP) mRNA, complete cds."					
		PARK et al. (Jan. 1999) "Vitamin D receptor polymorphism is associated with psoriasis", J. Invest. Dermatol., vol. 112, no. 1, pp. 113-16.					
		PINCELLI (Mar. 2000) "Nerve growth factor and keratinocytes: a role in psoriasis", Eur. J. Dermatol., vol. 10, no. 2, pp. 85-90.					
		KHOO et al. (1996) "Differential expression of cysteine-rich intestinal protein in liver and intestine in CCl <sub>4</sub> -induced inflammation", Am. J. Physiol., vol. 270, pp. G613-18.					
EXAMINER		P.N.D.C.			DATE CONSIDERED		
					6/28/04		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>GFN-5405CP</b>	SERIAL NO. <b>09/852,400</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT <b>William L. Trepicchio et al.</b>	
				FILING DATE <b>May 9, 2001</b>	
				GROUP <b>1623</b>	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<b>PN</b>	A1	Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8
	A2	Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7
	A3	Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800
	A4	Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22
	A5	Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40
	A6	Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
	A7	Fredriksson T, et al. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44
	A8	Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7
	A9	Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7
<b>PN</b>	A10	Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9
Examiner <b>P. Nolan</b>		Date Considered <b>6/28/04</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED

JAN 07 2002

TECH CENTER 1600/290

